Diabetes is a major stroke risk factor and is associated with poor functional recovery after stroke. Accumulating evidence indicates that the worsened outcomes may be due to hyperglycemia-induced cerebral vascular complications, especially disruption of the blood-brain barrier (BBB). The present study tested a hypothesis that the activation of hypoxia inducible factor-1 (HIF-1) was involved in hyperglycemia-aggravated BBB disruption in an ischemic stroke model. Non-diabetic control and Streptozotocin-induced type I diabetic mice were subjected to 90 min transient middle cerebral artery occlusion (MCAO) followed by reperfusion. Our results demonstrated that hyperglycemia induced higher expression of HIF-1α and vascular endothelial growth factor (VEGF) in brain microvessels after MCAO/reperfusion. Diabetic mice showed exacerbated BBB damage and tight junction disruption, increased infarct volume as well as worsened neurological deficits. Furthermore, suppressing HIF-1 activity by specific knock-out endothelial HIF-1α ameliorated BBB leakage and brain infarction in diabetic animals. Moreover, glycemic control by insulin abolished HIF-1α up-regulation in diabetic animals and reduced BBB permeability and brain infarction. These findings strongly indicate that HIF-1 plays an important role in hyperglycemia-induced exacerbation of BBB disruption in ischemic stroke. Endothelial HIF-1 inhibition warrants further investigation as a therapeutic target for the treatment of stroke patients with diabetes.
Introduction
Ischemic stroke is a leading cause of death and long-term disability in the United States and worldwide, and diabetes is the most rapidly increasing risk factor for stroke. Approximately 30-40% of ischemic stroke patients present with admission hyperglycemia, either due to diabetes or due to a generalized stress reaction (Gray et al., 2007) . The relative risk of cerebrovascular disease or stroke is 2 to 6-fold higher in diabetes (Rosamond et al., 2007) . In addition to the increased stroke incidence, diabetes and hyperglycemia are associated with worsened stroke outcomes, leading to increased mortality and poor functional recovery (Capes et al., 2001; Kruyt et al., 2010; Martini and Kent, 2007) . Since diabetic patients are at a higher risk of stroke and have poorer prognosis compared to the non-diabetic population, a better understanding on how diabetes affects ischemic stroke outcome is pivotal for developing better prevention and treatment strategies before and after an ischemic insult.
During ischemic stroke, cerebral ischemia and subsequent reperfusion result in harmful consequences, including the breakdown of the blood-brain barrier (BBB), which leads to severe neurologic deficits through aggravation of edema formation and brain hemorrhage (Borlongan et al., 2012; Jung et al., 2010; Latour et al., 2004) . Acute hyperglycemia increases infarct volume, brain swelling and hemorrhagic transformation in rat models (McBride et al., 2016) . The incidence and severity of BBB damage is markedly higher in stroke patients with diabetes or stress hyperglycemia than those without, implying a prominent role for high blood glucose in the development and exacerbation of BBB disruption (Baird et al., 2003; Capes et al., 2001; Rosso et al., 2015) . Moreover, in acute stroke patients who received tPA treatments, hyperglycemia was associated with increased mortality and worse clinical outcomes (Masrur et al., 2015) . However, the mechanisms underlying diabetes-and hyperglycemia-mediated exacerbation in ischemic brain injury remain largely unexplored and are of great importance in identifying novel therapeutic targets for cerebrovascular protection.
Hypoxia-inducible factor 1 (HIF-1) is a key transcription factor in response to hypoxia/ischemia. It is a heterodimer of two subunits, the regulatable HIF-1α and constitutively expressed and stable HIF-1β. The activity of HIF-1 is primarily determined by the level of the α subunit. HIF-1 is implicated in cerebral vascular disorders in various pathological conditions, such as ischemic stroke, sabarachnoid hemorrhage, and traumatic brain injury. Inhibition of HIF-1 ameliorates hypoxia- 
